MaxCyte Q3 net loss narrows 62% to $4.76 million; Q3 revenue rises 49% to $10.15 million

• MaxCyte’s third-quarter 2026 net loss narrowed 62% year over year to $4.76 million.
• Revenue climbed 49% to $10.15 million, while core revenue rose 27% to $8.16 million from a year earlier.
• The proposed acquisition of Akron Bio would expand its offering across cell therapy manufacturing.
• Full-year 2026 revenue guidance increased to at least $34.5 million, excluding the Akron acquisition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MaxCyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611100601PRIMZONEFULLFEED9873981) on November 10, 2026, and is solely responsible for the information contained therein.